Correspondence

Writing to the desk

The most valuable message this desk receives is a correction. A figure quoted loosely, a hazard ratio transposed, a trial that has since posted results, a regulatory status that has moved, or a peer-reviewed study on any of the five compounds reviewed here that belongs in the bibliography — each of those makes the review more accurate, and each is read and weighed.

Corrections that are easiest to act on name three things: the page, the exact passage in question, and the supporting source with a DOI or PubMed identifier where one exists. In that shape a proposed change can be checked against its source before anything is rewritten.

Editorial mailbox: editors@peptidecoalition.com

Beyond the desk's remit

So that no message goes unanswered for the wrong reason, several requests sit outside what this desk does. It cannot advise on, endorse, or comment on human use of any compound reviewed here. It cannot name a dose, schedule or route for any individual, and it will not do so under any framing. It cannot judge whether a finding from a cited trial applies to a particular person's circumstances. It does not sell, source, or help track down any compound from any supplier, and it cannot point the way to prescription medicines outside a licensed prescriber-patient relationship. It also cannot advise athletes subject to anti-doping rules: BPC-157 and CJC-1295 are both prohibited in sport, and the status of the others should be checked against the current list directly.

Semaglutide and bremelanotide are prescription medicines; thymalfasin is approved outside the United States; BPC-157 and CJC-1295 are approved nowhere. Anyone seeking medical guidance should take it to a licensed clinician in their own jurisdiction. Replies are not guaranteed and can lag.